Buy & Sell Veritone Inc (VERI) – Veritone Inc Price Today
Aura AI Summary
Key Stats
- $183.58MMarket Cap
- TechnologySector
- -45.86%3M Drawdown
- $213.89MEnterprise Value
- -Dividend Yield
- 85% Buy | 15% SellTrading Activity
- 3 daysTypical Hold Time
Veritone Inc (VERI) is currently valued at a market capitalization of $183.58M, with an enterprise value of $213.89M. Over the past 52 weeks, Veritone Inc has traded between a low of $1.22 and a high of $8.39, highlighting its annual price range. Over the past three months, Veritone Inc has recorded a drawdown of -45.86%, reflecting recent price volatility. On average, investors hold Veritone Inc for approximately 3 days, indicating typical investor behavior on the platform.
About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Most Recent News
NevGold upsizes financing to C$42M, advancing US antimony-gold project with near-term production plans.
NevGold Corp. has increased its brokered private placement financing from C$25 million to over C$42 million due to strong institutional demand. The Vancouver-based junior miner is developing the Limousine Butte gold-antimony project in Nevada, target...
Quantum Cyber secures exclusive drone tech license amid $55B US drone warfare budget boost
Quantum Cyber has secured an exclusive license for BP United's autonomous drone technology, including a sky defense platform capable of over 25 km range and fully autonomous operations. This move positions Quantum Cyber to capitalize on the Trump adm...
Corbus Pharmaceuticals to present at RBC and Jefferies healthcare conferences in May and June 2026
Corbus Pharmaceuticals Holdings, a clinical-stage biotech company focused on oncology and obesity therapies, announced CEO Yuval Cohen will present corporate updates and meet investors at two major healthcare conferences in New York: the RBC Capital ...